News | April 04, 2025
Lupin acquires UK-based Renascience Pharma for £12.3 million
The portfolio includes branded injectable cephalosporines for infectious diseases
The portfolio includes branded injectable cephalosporines for infectious diseases
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Amifampridine Tablets, 10 mg are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older.
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
We have big plans across our B2C and B2B businesses in India and abroad
the inspection conducted from January 27 to January 31, 2025
This rating reflects Lupin's leadership in environmental transparency and performance
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Subscribe To Our Newsletter & Stay Updated
